Introduction and Background
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in virtually all living cells that plays an indispensable role in cellular metabolism, energy production, and signalling. First identified by Arthur Harden and William John Young in 1906 during their investigations of fermentation, NAD+ has since emerged as one of the most studied molecules in the biological sciences. Over the past two decades, research has demonstrated that NAD+ functions far beyond its classical role as an electron carrier in redox reactions; it serves as a critical substrate for enzymes that regulate genomic stability, circadian rhythms, and cellular stress responses (Verdin, 2015).
The renewed interest in NAD+ biology stems largely from observations that intracellular NAD+ concentrations decline significantly with age across multiple tissues and organisms. This age-dependent depletion has been correlated with the onset of metabolic dysfunction, neurodegenerative conditions, and reduced capacity for DNA repair. The identification of NAD+ as a rate-limiting substrate for sirtuins and poly(ADP-ribose) polymerases (PARPs) has positioned it at the intersection of aging research and metabolic science, prompting extensive investigation into strategies for restoring cellular NAD+ levels (Imai and Guarente, 2014).
Biochemistry and Cellular Roles
NAD+ exists in two principal forms: the oxidised form (NAD+) and the reduced form (NADH). Together, this redox couple participates in over 500 enzymatic reactions within the cell, making it one of the most versatile cofactors in mammalian biochemistry. In oxidative phosphorylation, NADH donates electrons to Complex I of the mitochondrial electron transport chain, driving the proton gradient that fuels ATP synthase. In glycolysis, NAD+ serves as an obligate electron acceptor during the oxidation of glyceraldehyde-3-phosphate (Cantó et al., 2015).
Beyond its redox function, NAD+ acts as a consumed substrate in three principal classes of signalling enzymes. First, the sirtuins (SIRT1-7), a family of NAD+-dependent protein deacylases, cleave NAD+ to produce nicotinamide and O-acetyl-ADP-ribose during the removal of acyl groups from target proteins. Second, poly(ADP-ribose) polymerases (PARPs), particularly PARP1, consume NAD+ to synthesise poly(ADP-ribose) chains on target proteins in response to DNA strand breaks. Third, cyclic ADP-ribose synthases, including CD38 and CD157, hydrolyse NAD+ to generate calcium-mobilising second messengers. Critically, all three enzyme classes degrade NAD+ stoichiometrically, meaning that their activity directly depletes the cellular NAD+ pool (Chini et al., 2017).
Biosynthesis Pathways
Mammalian cells synthesise NAD+ through three principal routes. The de novo pathway converts dietary tryptophan to NAD+ via the kynurenine pathway, a multi-step process that is particularly active in hepatic tissue. The Preiss-Handler pathway utilises nicotinic acid (vitamin B3) as a precursor, converting it through nicotinic acid mononucleotide to NAD+. However, the salvage pathway is quantitatively the most important route for maintaining intracellular NAD+ homeostasis in most tissues. In this pathway, nicotinamide generated by sirtuin and PARP activity is recycled back to NAD+ through the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT), which catalyses the formation of nicotinamide mononucleotide (NMN). NMN is subsequently adenylated by nicotinamide mononucleotide adenylyltransferases (NMNATs) to regenerate NAD+ (Yoshino et al., 2018).
NAD+ Decline in Aging
A substantial body of evidence now documents the progressive decline of NAD+ levels during the aging process. Studies in murine models have demonstrated that tissue NAD+ concentrations in the liver, skeletal muscle, adipose tissue, and brain decrease by approximately 30-50% between young adulthood and old age. This decline has been observed across multiple species, including Caenorhabditis elegans, Drosophila melanogaster, and rodents, suggesting an evolutionarily conserved phenomenon (Gomes et al., 2013).
Several mechanisms have been proposed to account for this age-related NAD+ depletion. Research by Camacho-Pereira and colleagues demonstrated that expression and activity of CD38, a major NAD+-consuming ectoenzyme, increase substantially with age in multiple tissues. Genetic ablation of CD38 in aged mice was shown to restore NAD+ levels and improve mitochondrial function, implicating CD38 upregulation as a primary driver of age-related NAD+ decline (Camacho-Pereira et al., 2016). Additionally, chronic low-grade inflammation associated with aging (often termed "inflammaging") activates immune cells that express high levels of CD38, creating a positive feedback loop that further accelerates NAD+ depletion. Concurrent reductions in NAMPT expression with age further impair the salvage pathway, diminishing the cell's capacity to regenerate NAD+ from nicotinamide (Chini et al., 2017).
The consequences of NAD+ decline are wide-ranging. In a landmark study, Gomes et al. demonstrated that reduced NAD+ levels in aged mice induced a pseudohypoxic transcriptional state by disrupting the nuclear-mitochondrial communication axis mediated by hypoxia-inducible factor 1-alpha (HIF-1α). Under normal conditions, adequate NAD+ supports SIRT1 activity, which maintains HIF-1α in an inactive state. When NAD+ falls below a critical threshold, SIRT1 activity diminishes, HIF-1α stabilises, and the resulting transcriptional programme shifts the cell toward glycolytic metabolism and away from oxidative phosphorylation, recapitulating metabolic signatures observed in aged tissues (Gomes et al., 2013).
Sirtuin Pathway Activation
The sirtuins comprise a family of seven NAD+-dependent deacylases (SIRT1-7) with distinct subcellular localisations and substrate specificities. SIRT1, SIRT6, and SIRT7 are predominantly nuclear; SIRT3, SIRT4, and SIRT5 reside in the mitochondria; and SIRT2 is primarily cytoplasmic. Because these enzymes require NAD+ as a stoichiometric co-substrate, their activity is directly coupled to the cellular NAD+/NADH ratio, positioning sirtuins as metabolic sensors that translate the cell's energetic status into epigenetic and post-translational modifications (Imai and Guarente, 2014).
SIRT1 has received particular attention in the context of aging research. Through deacetylation of transcription factors including PGC-1α, FOXO1, FOXO3a, and NF-κB, SIRT1 modulates mitochondrial biogenesis, oxidative stress resistance, inflammatory signalling, and autophagy. Studies in murine models have demonstrated that pharmacological or genetic augmentation of SIRT1 activity confers protection against age-associated metabolic decline. SIRT3, the primary mitochondrial deacetylase, plays an analogous role within the mitochondrial matrix, where it deacetylates key enzymes of the tricarboxylic acid cycle and the electron transport chain to maintain oxidative phosphorylation efficiency. Camacho-Pereira et al. demonstrated that age-related NAD+ depletion driven by CD38 accumulation leads to reduced SIRT3 activity, resulting in hyperacetylation of mitochondrial proteins and consequent mitochondrial dysfunction (Camacho-Pereira et al., 2016).
The therapeutic implications of sirtuin activation through NAD+ repletion have been explored in several preclinical models. Zhang et al. demonstrated that supplementation with the NAD+ precursor nicotinamide riboside (NR) in aged mice restored NAD+ levels, improved mitochondrial membrane potential, and enhanced muscle stem cell function, resulting in measurable improvements in life span. These effects were shown to be dependent on the mitochondrial unfolded protein response (UPRmt) and the prohibition/SIRT1 signalling axis (Zhang et al., 2016).
DNA Repair Mechanisms
NAD+ plays a central role in the cellular DNA damage response through its function as the obligate substrate for PARP1, the principal sensor of single-strand DNA breaks. Upon detecting a lesion, PARP1 is rapidly activated and consumes substantial quantities of NAD+ to synthesise poly(ADP-ribose) (PAR) chains on histones and repair factors at the damage site. These PAR chains serve as scaffolds for the recruitment of downstream repair machinery, including XRCC1, DNA ligase III, and DNA polymerase β. Under conditions of extensive DNA damage, PARP1 hyperactivation can deplete cellular NAD+ pools sufficiently to compromise sirtuin activity and trigger metabolic catastrophe (Fang et al., 2014).
The interplay between PARP1 and SIRT1 for a shared and limited NAD+ pool represents a critical regulatory node in the aging process. Fang and colleagues provided compelling evidence for this model in the context of xeroderma pigmentosum group A (XPA), a nucleotide excision repair disorder. In XPA-deficient cells, persistent unrepaired DNA lesions drive constitutive PARP1 hyperactivation, resulting in severe NAD+ depletion that reduces SIRT1 activity below the threshold required for effective mitophagy. The consequent accumulation of dysfunctional mitochondria was shown to be reversible through NAD+ supplementation, which restored SIRT1-dependent mitophagy and improved cellular bioenergetics (Fang et al., 2014). This competition model has since been extended to the normal aging process, where the cumulative burden of DNA damage in aged cells is hypothesised to chronically activate PARP1, progressively diverting NAD+ away from sirtuin-mediated maintenance pathways (Verdin, 2015).
Current Research Directions
Contemporary NAD+ research is broadly organised around three principal axes: precursor supplementation, enzymatic modulation, and tissue-specific NAD+ dynamics. The precursor approach centres on the administration of NMN and NR as bioavailable NAD+ intermediates. Preclinical studies have demonstrated that both NMN and NR effectively elevate tissue NAD+ levels in rodent models and ameliorate a range of age-associated phenotypes, including insulin resistance, vascular endothelial dysfunction, neuroinflammation, and cardiac hypertrophy (Rajman et al., 2018).
A parallel line of investigation targets the enzymes responsible for NAD+ degradation. CD38 inhibitors have demonstrated efficacy in preclinical models, restoring NAD+ levels in aged mice without the need for precursor supplementation. This approach has the theoretical advantage of addressing the root cause of age-related NAD+ decline rather than merely compensating for increased consumption. PARP inhibitors, already approved for certain oncological indications, represent another potential strategy, although their effects on NAD+ homeostasis in the context of aging remain an active area of investigation (Camacho-Pereira et al., 2016).
Emerging research has also begun to elucidate the tissue- and compartment-specific regulation of NAD+ metabolism. The discovery that extracellular NAMPT (eNAMPT), secreted in extracellular vesicles from adipose tissue, functions as a systemic NAD+ biosynthetic enzyme has introduced the concept of inter-organ NAD+ communication. This finding suggests that age-related NAD+ decline may not be a purely cell-autonomous process but may involve disruptions to systemic metabolic signalling networks (Imai and Guarente, 2014).
Furthermore, the intersection of NAD+ biology with circadian rhythm regulation has opened new avenues of investigation. NAMPT expression is under direct circadian control via CLOCK:BMAL1, creating an oscillatory pattern of NAD+ biosynthesis that couples the molecular clock to metabolic output. Age-related disruptions to circadian function may therefore both result from and contribute to NAD+ depletion, creating a degenerative cycle that accelerates metabolic decline (Cantó et al., 2015).
Translational Considerations
The translation of preclinical NAD+ research into clinical investigation remains an active frontier. Early-phase human studies have established the pharmacokinetic profiles and tolerability of NR and NMN in healthy volunteers, confirming that oral administration elevates circulating NAD+ metabolites in a dose-dependent manner (Yoshino et al., 2018). However, substantial questions remain regarding optimal tissue targeting, long-term safety, and the identification of reliable biomarkers for monitoring intracellular NAD+ status in clinical settings. The complexity of NAD+ metabolism, with its multiple biosynthetic routes, consuming enzymes, and compartmentalised pools, presents significant challenges for the design of intervention studies aimed at demonstrating functional outcomes in human aging (Rajman et al., 2018).
In summary, NAD+ occupies a central position in cellular metabolism and has emerged as a molecule of considerable interest in aging research. The convergence of evidence from biochemical, genetic, and pharmacological studies supports a model in which age-related NAD+ decline contributes to sirtuin hypofunction, impaired DNA repair capacity, mitochondrial dysfunction, and metabolic dysregulation. Ongoing research continues to refine our understanding of the mechanisms governing NAD+ homeostasis and to explore the translational potential of NAD+ repletion strategies in model systems.